Article

Germ-line mutations in epidermal growth factor receptor (EGFR) are rare but may contribute to oncogenesis: A novel germ-line mutation in EGFR detected in a patient with lung adenocarcinoma

Laboratorio de Oncología Molecular, Instituto Universitario de Oncología del Principado de Asturias, Hospital Universitario Central de Asturias, (Celestino Villamil s/n), Oviedo, Spain.
BMC Cancer (Impact Factor: 3.32). 05/2011; 11(1):172. DOI: 10.1186/1471-2407-11-172
Source: PubMed

ABSTRACT A subset of lung cancer patients harbour EGFR somatic mutations in their tumours and are candidates for treatment with EGFR tyrosine kinase inhibitors. In a few cases EGFR mutations have also been found in the germ line, suggesting a role in lung carcinogenesis. Objetives of this study were: 1) To analyze the EGFR gene mutations in a population diagnosed with lung adenocarcinoma from Northern Spain. 2) To determine the frequency of a new germ-line mutation found in our laboratory as well as the frequency in our population of three other EGFR germ-line mutations detected by other authors. 3) To determine whether the novel mutation detected may have a functional effect on the EGFR protein.
Tumour DNA samples were obtained from frozen or paraffin embedded tumour tissues. Samples of DNA from peripheral blood cells were obtained from 912 individuals with lung cancer recruited from the CAPUA study 12, 477 unrelated healthy donor individuals and 32 individuals with other types of cancer. EGFR gene exons 18 to 21 were studied by direct standard dideoxy sequencing. Specific mutations were determined either by direct sequencing or by specific RFLP analysis. Cell lines were transfected with EGFR-mutant plasmids and analysed by western blot with antibodies specific for total or phosphorylated-EGFR.
We found EGFR mutation in 12 of the 71 tumour samples (17%). One tumour contained two mutations. One mutation (p.R776G) was present as a germ line. Using an RFLP analysis, this mutation was not found in 954 alleles from healthy individuals studied, concluding that it is not a polymorphism. The mutation was not found either in genomic DNA from 912 lung cancer patients. Three additional EGFR germ-line mutations that were already described were not found in any of the studied samples. These observations show that EGFR mutated alleles are rare in the population. In vitro studies revealed that tyrosine autophosphorylation is enhanced in p.R776G-mutant EGFR when compared with wild-type EGFR. This enhanced autophosphorylation in the absence of ligand may be associated with a proliferative advantage.
Germ-line mutations in EGFR are rare but may contribute to oncogenesis.

Download full-text

Full-text

Available from: Milagros Balbin, Aug 17, 2015
0 Followers
 · 
147 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Epidermal growth factor receptor (EGFR) mutations are associated with the response to EGFR inhibitors in patients with non-small-cell lung cancer (NSCLC). We sought to investigate EGFR aberrations in patients with diverse advanced cancers.Patients and methodsPatients referred to the phase I clinic were evaluated for the presence of EGFR mutations and response to therapy.ResultsEGFR aberrations were detected in 34 of 958 patients (3.5%). Though EGFR mutations were most frequent in NSCLC (21 of 131, 16%), they were also present in a variety of other solid tumors (13 of 827 patients, 1.6%) including adrenocortical (1/10 patients), skin (1/24), breast (1/55), carcinoid (1/8), cholangiocarcinoma (1/20), head and neck (1/61), ovarian (1/84), parathyroid (1/1), salivary gland (1/20), renal (1/17), sarcoma (2/38), and thymic carcinomas (1/7). Of the 13 EGFR aberration-positive non-NSCLC patients (median number of prior systemic therapies = 3), 6 had treatment with an EGFR inhibitor. Two patients (diagnosis = parathyroid tumor and basal cell carcinoma) achieved stable disease (SD), lasting 6 and 7 months, respectively.Conclusion We found EGFR aberrations in 1.6% of a large group of patients with diverse tumors other than NSCLC, and treatment with an EGFR inhibitor could be associated with prolonged SD.
    Annals of Oncology 11/2012; 24(3). DOI:10.1093/annonc/mds524 · 6.58 Impact Factor
  • Journal of Clinical Oncology 01/2013; 31(10). DOI:10.1200/JCO.2012.42.1586 · 18.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces extracellular growth factor signaling to the cell. It has become an important therapeutic target with tyrosine kinase inhibitors (TKIs) for the treatment of lung adenocarcinomas harboring activating mutations in the kinase domain of the EGFR gene. The two most common EGFR mutations are short in-frame deletions of exon 19 and point mutation L858R in exon 21. Together, these mutations account for � 85% of all known EGFR alterations, and both have been associated with sensitivity to TKIs gefitinib and erlotinib in preclinical and clinical studies. Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinicopathologic characteristics has proven inadequate. Today, direct sequencing is the gold standard for any mutation analysis. However, in most lung cancer patient samples, the proportion of tumor-containing cells is too small to be suitable for sequencing-based analysis because of its low sensitivity. Thus, a large number of commercially available detection kits for in vitro diagnostics, most of them based on real-time polymerase chain reaction (PCR), have been developed over the past few years; these in vitro diagnostic kits greatly increase detection sensibility but identify only the most common and clinically relevant alterations discovered to date. Although L858R EGFR mutation is one alteration that all these kits are developed to identify because of its importance, we have found one patient in whom the COBAS EGFR mutation test (Roche Molecular Systems, Branchburg, NJ) failed to detect it; the mutation was, nevertheless, confirmed by both direct sequencing and another commercial kit (Therascreen EGFR RGQ PCR;QIAGEN Manchester, Manchester, United Kingdom). This challenging sample contained another mutation in the EGFR gene, only 10 residues away from L858R.
    Journal of Clinical Oncology 07/2013; 31(26). DOI:10.1200/JCO.2012.47.3512 · 18.43 Impact Factor
Show more